Anthropic announced on Apr. 16 that Novartis CEO Vas Narasimhan has joined its board of directors, marking a significant move toward embedding artificial intelligence in drug development and the broader life sciences sector.
Narasimhan's appointment is seen as a step to ensure responsible progress in AI within healthcare, balancing technological advancement with shareholder interests. Neil Shah, chair of Anthropic’s Long-Term Benefit Trust—which operates independently and without financial stake—said in a statement that Narasimhan will help the company “responsibly balance” its mission of advancing AI for humanity with its obligation to deliver value to shareholders.
In his own remarks, Narasimhan said, “Anthropic is setting the standard for how AI should be developed to benefit humanity,” emphasizing that AI is improving understanding of disease biology and aiding drug design, which he believes is “accelerating solutions to some of the hardest scientific challenges.”
Recently, Anthropic has increased investment in healthcare-focused models. In October 2025, it launched Claude Life Sciences, an artificial intelligence model tailored for biopharma professionals such as clinical trial coordinators and regulatory managers. The company’s services have attracted large pharmaceutical firms including Sanofi, Novo Nordisk and AbbVie, as well as smaller companies like Genmab and 10X Genomics.
Earlier this month, Anthropic acquired New York startup Coefficient Bio for $400 million. While details about Coefficient Bio remain limited, its co-founders Nathan Frey and Samuel Stanton previously worked on machine learning at Roche’s Genentech.
Industry experts say that advanced machine learning models are also influencing broader trends in biotech finance. Tyrone Lam, chief business officer at GATC Health—a technology-driven biotech firm—said via email that companies using AI not only accelerate discovery but also improve communication about risk to investors: “The companies drawing the most serious investor attention right now... are using AI not just as a discovery accelerator but as a risk communication tool.”
As more biopharma organizations integrate artificial intelligence into their operations and leadership structures like Anthropic's latest board addition suggests further expansion ahead.
